InMed Pharmaceuticals Inc. (“
InMed” or the
“
Company”) (
Nasdaq: INM), a
leader in the pharmaceutical research, development and
manufacturing of rare cannabinoids and cannabinoid analogs, today
announces the Company has entered into a service contract (the
“Contract”) with Brio Financial Group (“Brio”) to provide senior
financial leadership and bookkeeping services. Pursuant to the
Contract, Mr. Jonathan Tegge, a member of Brio, will assume the
role of Interim Chief Financial Officer for the Company effective
December 12, 2022.
Brio is a financial and management consulting
group based in Bridgewater, New Jersey. The firm provides
outsourced financial management and financial reporting support to
small and middle market entities. Currently, the team provides
consulting services to over 50 private and publicly traded
companies.
Additionally, the Company announces that its
auditor, KPMG LLP (“KPMG”), has resigned effective as of December
8, 2022, and that the Audit Committee of the Board of Directors of
the Company approved the engagement of Marcum LLP (“Marcum”) as its
auditor, subject to Marcum’s completion of their client acceptance
procedures. Marcum will stand for appointment at the Company’s
Annual General Meeting, currently scheduled for Thursday, December
15, 2022 (the “Meeting”). KPMG has confirmed that there are no
reportable events (as such term is defined in National Instrument
51-102 – Continuous Disclosure Obligations (“NI
51-102”)).
Eric A. Adams, Chief Executive Officer of InMed,
commented, "We are delighted to engage Marcum as the Company’s new
auditors. We believe that Marcum's breadth of expertise and its
focus on mid-sized companies, including cross-border operations,
makes Marcum well suited to support our efforts to deliver the high
level of financial transparency and reporting to which our
shareholders are accustomed.”
InMed has provided KPMG with a copy of the Form
8-K announcing their resignation and KPMG have furnished a letter
addressed to the Securities and Exchange Commission stating that it
has no disagreement with the disclosures therein.
To learn more about Marcum, please visit their
website at https://www.marcumllp.com
Shareholder Meeting Details
While the Company intended to re-appoint the
KPMG at the upcoming Meeting, it now wishes to amend the
appointment of auditor resolution provided for in the Management
Information Circular dated October 28, 2021 (the “Circular”), and
to recommend the appointment of Marcum.
The Circular has been mailed to shareholders and
is available for viewing on SEDAR. Except as described above, the
Circular remains unchanged from the version that was mailed to the
shareholders of the Company and previously filed on SEDAR.
The Circular and Form of Proxy previously
distributed to registered shareholders in connection with the
Meeting confers discretionary authority upon management (or other
person designated as proxy therein) to vote on amendments or
variations of matters coming before the Meeting. Management intends
to rely on the discretionary authority granted in the Circular and
form of proxy to vote FOR the appointment of Marcum as the
Company’s auditor.
If a registered shareholder has submitted a
management proxy and does not wish the proxy to be voted in this
manner, they may revoke their proxy at any time prior to using it:
(a) by depositing an instrument in writing, including another
completed form of proxy, executed by such registered shareholder or
by his, her or its attorney authorized in writing or by electronic
signature; or (b) by transmitting by facsimile or electronic means,
a revocation signed, subject to the Business Corporations Act
(British Columbia), by electronic signature, delivered to the Proxy
Department, Computershare Investor Services Inc., 100 University
Avenue, 9th Floor, Toronto, Ontario, M5J 2Y1, or to the address of
the office of InMed at Suite 310 – 815 West Hastings St.,
Vancouver, British Columbia, V6C 1B4, at any time prior to 2:00
p.m. (PST) on the last business day preceding the day of the
Meeting or any adjournment or postponement thereof; or (c) by
personally attending the Meeting and voting the registered
shareholders’ common shares; or (d) in any other manner permitted
by law.
If a non-registered or beneficial shareholder
wishes to revoke their previously given voting instructions, they
must contact the broker or other intermediary to whom they provided
their voting instruction forms and comply with any and all
applicable requirements of such broker or intermediary. A broker or
other intermediary may not be able to revoke voting instructions if
it receives insufficient notice of revocation, and any
non-registered shareholder wishing to revoke their voting
instructions should contact such broker or intermediary in
sufficient time to ensure that their revocation of voting
instructions is received.
If as a registered shareholder you use your
control number to access the Meeting and you accept the terms and
conditions, you will be revoking any and all previously submitted
proxies for the Meeting and will be provided with the opportunity
to vote by online ballot on the matters put forth at the
Meeting.
If you have any questions about any of the
information in the Circular or this press release or require
assistance in completing your form of proxy or voting instruction
form, please consult your financial, legal, tax and other
professional advisors or the Company’s strategic shareholder
advisor and proxy solicitation agent, Computershare, by telephone
at 1-866-732-VOTE (8683) (toll-free in North America) or at
+1-312-588-4290 outside of North America, or by the internet at
www.investorvote.com.
About InMed:
InMed Pharmaceuticals is a global leader in the
research, development and manufacturing of rare cannabinoids,
including clinical and preclinical programs targeting the treatment
of diseases with high unmet medical needs. We also have significant
know-how in developing proprietary manufacturing approaches to
produce cannabinoids for various market sectors. For more
information, visit www.inmedpharma.com.
Investor Contact: Colin ClancyVice President,
Investor RelationsT: +1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about, but are not limited to: general
business, economic, competitive, political and social
uncertainties; uncertain and volatile equity and capital markets;
lack of, or access to, capital; future demand for InMed’s business
and risks related to the same; statements with respect to the
appointment of a new Interim Chief Executive Officer and relating
timings; statements with respect to the Company’s auditor including
the engagement and appointment of a successor auditor; the
anticipated timing to complete the change in auditors and file
associated materials pursuant to applicable U.S. securities laws
and NI 51-102; and, any proposed amendments to the resolutions at
the Company’s Meeting.
With respect to the forward-looking information
contained in this news release, InMed has made numerous assumptions
regarding, among other things: the ability to obtain all necessary
regulatory approvals on a timely basis, or at all; and, continued
economic and market stability. While InMed considers these
assumptions to be reasonable, these assumptions are inherently
subject to significant business, economic, competitive, market and
social uncertainties and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed’s business is disclosed
in InMed’s Annual Report on Form 10-K and other filings with the
SEC on www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
InMed Pharmaceuticals (NASDAQ:INM)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024